This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 3 of 564

Biotech Stock Mailbag: Vanda, Navidea, Provectus

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

08:00AM 06/13/14

EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel

By Adam Feuerstein

EnteroMedics and its VBLOC "fat-zapping" implantable medical device will be the focus of an FDA advisory panel meeting next Tuesday, June 17. If FDA follows historical form, the agency's review of VBLOC's safety and efficacy will be available publicly tomorrow morning.

08:00AM 06/12/14

FDA Delays Decision on Orexigen Obesity Pill by 3 Months

By Adam Feuerstein

FDA needs more time to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of heart-safety related outcomes for Contrave, Orexigen said

06:48AM 06/11/14

Inovio CEO Preps Retail Investors for Drug Study Failure

By Adam Feuerstein

Inovio Pharmaceuticals CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from the VGX-3100 study should be announced any day, but I suspect Inovio already has data in hand. Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?

12:23PM 06/10/14

Achillion Hep C Drug Update is Well Timed

By Adam Feuerstein

Talk about uncanny timing, one day after Achillion Pharmaceuticals rips higher on takeover speculation, the company announces the lifting of an FDA clinical hold on its lead hepatitis C drug candidate and the start of a new study with a second hepatitis C compound.

08:36AM 06/10/14

Dendreon CEO Exits Ahead of Big Debt Payment

By Adam Feuerstein

The desperate Dendreon debacle just descended into despondency with the abrupt departure of Chairman and CEO John Johnson, citing "personal reasons."

04:38PM 06/09/14

Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday

By Adam Feuerstein

Selling weight-loss pills to fat Americans is clearly more difficult than Vivus and Arena envisioned. Orexigen will face the same challenges, but of the three companies, it has the best marketing partner in Takeda because of its metabolic drug expertise.

12:43PM 06/09/14

Achillion Pharma Might be Next Hep C Takeout Target

By Adam Feuerstein

Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.

09:22AM 06/09/14

Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal

By Adam Feuerstein

With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from M&A. But Merck chief scientitist Roger Perlmutter is no dummy, so his decision to spend almost $4 billion on Idenix says the hepatitis C treatment market may have a much longer tail than many believed.

08:27AM 06/09/14

Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition

By Adam Feuerstein

I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail means for biotech investor sentiment, but I'll leave the interpretations up to you.

10:32AM 06/06/14

Page 3 of 564

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs